Related Experiment Video
Updated: Mar 1, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Acute effects of cinacalcet on arterial stiffness and ventricular function in hemodialysis patients: A randomized
Aurélie Poulin1, Pierre-Luc Bellemare, Catherine Fortier
1CHU de Québec Research Center, L'Hôtel-Dieu de Québec Hospital Department of Medicine, Faculty of Medicine, Université Laval, Québec, QC, Canada.
Insights
Cinacalcet, a medication that lowers calcium and parathyroid hormone, did not significantly improve arterial stiffness or cardiac function in patients with end-stage kidney disease. This 7-day study found no significant changes in blood pressure or vascular stiffness parameters.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Pharmacology
Background:
- Serum calcium (Ca) influences vascular tone and myocardial contractility.
- Previous research indicated hemodialysis-induced Ca reduction improves arterial stiffness.
- Cinacalcet, a calcimimetic, lowers Ca and parathyroid hormone (PTH).
Purpose of the Study:
- To investigate if acute Ca lowering with cinacalcet improves vascular stiffness.
- To assess the impact of cinacalcet on myocardial diastolic dysfunction.
Main Methods:
- Double-blinded, randomized, placebo-controlled crossover study.
- 21 end-stage kidney disease patients on hemodialysis received placebo-cinacalcet or cinacalcet-placebo for 7 days.
- Arterial stiffness (cf-PWV, cr-PWV, carotid distension) and cardiac function (echocardiography) were assessed.
Main Results:
- Cinacalcet significantly reduced PTH and ionized Ca levels.
- No significant reduction in carotid-femoral pulse wave velocity (cf-PWV) was observed.
- No significant changes in central blood pressure, brachial/carotid stiffness, or echocardiographic parameters were found.
Conclusions:
- One week of daily cinacalcet (30 mg) did not significantly impact arterial stiffness.
- The treatment showed no significant effect on peripheral/central blood pressures or cardiac function.
- Further research may be needed to explore longer-term effects or different dosages.
Background:
Serum calcium concentration (Ca) plays an essential role in a vascular muscle tone and myocardial contractility. Previously, we showed that acutely lowering Ca by hemodialysis reduced arterial stiffness. Cinacalcet is a calcimimetic that lowers Ca and parathyroid hormone (PTH). The aim of the present study was to examine whether acute lowering of Ca by cinacalcet improves vascular stiffness and myocardial diastolic dysfunction.
Method:
This is a double-blinded randomized placebo-controlled crossover study that included 21 adult patients with end-stage kidney disease undergoing chronic hemodialysis. Subjects were assigned to placebo-cinacalcet (30 mg) or cinacalcet-placebo sequence. After each treatment period (7 days), aortic, brachial, and carotid stiffness were determined by examining carotid-femoral pulse wave velocity (cf-PWV), carotid-radial PWV (cr-PWV), and carotid distension. A central pulse wave profile was determined by radial artery tonometry and cardiac function was evaluated by echocardiography.
Results:
Cinacalcet reduced PTH (483 [337-748] to 201 [71-498] ng/L, P < .001) and ionized Ca (1.11 [1.08-1.15] to 1.05 [1.00-1.10] mmol/L, P = .04). Cinacalcet did not reduced cf-PWV significantly (12.2 [10.4-15.4] to 12.2 [11.0-14.6] m/s, P = .16). After adjustments for mean blood pressure, sequence, carryover, and treatment effects, cf-PWV was not significantly lowered by cinacalcet (-0.35 m/s, P = .139). There were no significant changes in central blood pressures, brachial and carotid stiffness, and echocardiographic parameters.
Conclusion:
In this study, 30 mg daily cinacalcet for 1 week did not have any significant impact on peripheral and central blood pressures, arterial stiffness parameters, or cardiac function (NCT01250405).
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Cardiac Catheterization I: Pre-Procedure Overview

